The effect of baricitinib was similar to ruxolitinib, causing a significant increase in antibody-mediated infection of macrophages by both delta and omicron viruses, and a concomitant significant decrease in the production of IFNα and CXCL10. This evidence concerns the gene IFNA1 and infection.